Bellevue Group Ag Seagen Inc. Transaction History

Bellevue Group Ag

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$187.64 - $206.25 $131,348 - $144,375	-700 Reduced 3.08%	22,000 $4.23 Million
Q1 2023 May 15, 2023	BUY	$127.59 - $203.08 $9,441 - $15,027	74 Added 0.33%	22,700 $4.6 Million
Q4 2022 Feb 14, 2023	SELL	$117.37 - $139.17 $2.38 Million - $2.83 Million	-20,300 Reduced 47.29%	22,626 $2.91 Million
Q3 2022 Nov 14, 2022	SELL	$135.27 - $180.11 $872,491 - $1.16 Million	-6,450 Reduced 13.06%	42,926 $5.87 Million
Q2 2022 Aug 11, 2022	SELL	$108.81 - $179.33 $111,421 - $183,633	-1,024 Reduced 2.03%	49,376 $8.74 Million
Q1 2022 May 13, 2022	BUY	$119.61 - $157.85 $526,284 - $694,540	4,400 Added 9.57%	50,400 $7.26 Million
Q4 2021 Feb 10, 2022	SELL	$142.57 - $190.86 $1.06 Million - $1.41 Million	-7,400 Reduced 13.86%	46,000 $7.11 Million
Q3 2021 Nov 12, 2021	BUY	$142.45 - $169.82 $3.69 Million - $4.4 Million	25,900 Added 94.18%	53,400 $9.07 Million
Q2 2021 Aug 12, 2021	SELL	$135.08 - $161.1 $1.05 Million - $1.26 Million	-7,800 Reduced 22.1%	27,500 $4.34 Million
Q1 2021 May 12, 2021	SELL	$137.51 - $190.8 $1.55 Million - $2.16 Million	-11,300 Reduced 24.25%	35,300 $4.9 Million
Q4 2020 Feb 16, 2021	BUY	$164.63 - $211.93 $7.67 Million - $9.88 Million	46,600 New	46,600 $8.16 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

Stay updated on Bellevue Group Ag with notifications on news.